Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real‐world case series
Francesca Palandri(Istituto Oncologico Romagnolo), Mario Tiribelli(University of Udine), Giulia Benevolo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Gabriele Fontana(Board of the Swiss Federal Institutes of Technology), Eloise Beggiato, Giuseppe A. Palumbo(University of Catania), Marian Loffredo(Istituto di Ematologia di Bologna), Erika Morsia(Marche Polytechnic University), Massimo Breccia(San Antonio College), Filippo Branzanti(University of Bologna), Alberto Dedola(Istituto di Ematologia di Bologna)
Cited by 6
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|181
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
|American Journal of Hematology|2020|136
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response
|European Journal Of Haematology|2016|90